Background: Lipoxygenases are a family of enzymes which dioxygenate unsaturated fatty acids, thus initiating lipoperoxidation of membranes, the synthesis of signalling molecules as well as inducing structural and metabolic changes in the cell. The Lox enzymes in mammals, 12-LO and 15-LO, are classified with respect to their positional specificity of the deoxygenation of their most common substrate, arachidonic acid. The metabolism of arachidonic acid leads to the generation of biologically active metabolites that have been implicated in cell growth and proliferation, as well as survival and apoptosis. 15-Lipoxygenase acts in physiological membrane remodeling and the pathogenesis of atherosclerosis, inflammation and carcinogenesis. It is highly regulated and expressed in a tissue- and cell-type-specific fashion. IL-4 and IL-13 play important roles in transactivating the 15-LO gene. Overexpression of 15-LO type 1 in prostate cancer contributes to the cancer progression by regulating IGF-1R expression and activation. 15-lipoxygenase, type II (15-LO2) is important for the conversion of arachidonic acid to 15S-hydroperoxyeicosatetraenoic acid. It is a cytoplasmic protein expressed primarily in cornea, lung, hair and prostate.
Description: Rabbit polyclonal to 15 Lipoxygenase 2
Immunogen: KLH conjugated synthetic peptide derived from 15 Lipoxygenase 2
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 76 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
